Harrow Inc HROW
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $38.93
- Day Range
- $38.09–39.52
- 52-Week Range
- $28.54–54.85
- Bid/Ask
- $37.77 / $39.21
- Shares Outstanding
- 37.28M
- Market Cap
- $1.43B
- Volume/Avg
- 374,960 / 731,433
Key Statistics
- Price/Earnings (Normalized)
- 431.64
- Price/Sales
- 5.20
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 373
- Website
- https://www.harrow.com
Valuation
|
Metric
|
HROW
|
|---|---|
Price/Earnings (Normalized) | 431.64 |
Price/Book Value | 48.87 |
Price/Sales | 5.20 |
Price/Cash Flow | 42.49 |
Price/Earnings
HROW
Financial Strength
|
Metric
|
HROW
|
|---|---|
Quick Ratio | 2.14 |
Current Ratio | 2.48 |
Interest Coverage | 0.52 |
Quick Ratio
HROW
Profitability
|
Metric
|
HROW
|
|---|---|
Return on Assets (Normalized) | 0.12% |
Return on Equity (Normalized) | 1.00% |
Return on Invested Capital (Normalized) | 6.25% |
Return on Assets
HROW
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| Bkbxrmwn | Nfzjx | $67B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Fslvphth | Plmjlg | $40B | |||
| Haleon PLC ADR
HLN
| Znfcgylg | Vpmj | $40B | |||
| Zoetis Inc Class A
ZTS
| Kfbcltpl | Pmmg | $33B | |||
| Viatris Inc
VTRS
| Zmrkdrlg | Fjh | $19B | |||
| Elanco Animal Health Inc
ELAN
| Djl | Yrtfk | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Wnmfkwqmd | Cnzy | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| Cxqlcvf | Xfpp | $6B | |||
| Prestige Consumer Healthcare Inc
PBH
| Fkbcxqv | Fcztry | $2B | |||
| Perrigo Co PLC
PRGO
| Rghmmvhj | Xlkk | $2B |
United States